Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.49 |
| ▸ | CNR2 | P34972 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380596 | 0.92 | CNR1 (0.53) | CNR1CNR2KCNH2 | |
| SCHEMBL2771186 | 0.91 | CNR1 (0.51) | CNR1CNR2KCNH2 | |
| SCHEMBL1380176 | 0.91 | CNR1 (0.46) | CNR1CNR2KCNH2 | |
| SCHEMBL1377324 | 0.90 | OPRL1 (0.51) | CNR1KCNH2 | |
| SCHEMBL1377190 | 0.90 | CNR1 (0.51) | CNR1CNR2KCNH2 | |
| SCHEMBL2769031 | 0.89 | CNR1 (0.50) | CNR1CNR2KCNH2 | |
| SCHEMBL1380231 | 0.87 | CNR1 (0.52) | CNR1CNR2KCNH2 | |
| SCHEMBL1380503 | 0.87 | CNR1 (0.48) | CNR1CNR2KCNH2 | |
| SCHEMBL1377638 | 0.85 | CNR1 (0.53) | CNR1CNR2KCNH2 | |
| SCHEMBL2770695 | 0.85 | OPRL1 (0.56) | CNR1CNR2KCNH2MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4723514-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| EP-1720837-B1 | DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY | SANOFI AVENTIS (FR) | 2010-04-28 | — | — | EP | claimed |
| US-7294645-B2 | Derivatives of N′-(1,5-diphenyl-1H-pyrazol-3-yl) sulfonamide with CB1 receptor affinity | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | claimed |
| US-20070021486-A1 | DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE WITH CB1 RECEPTOR AFFINITY | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | claimed |
| EP-1720837-A1 | DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY | Sanofi-Aventis (FR) | 2006-11-15 | — | — | EP | claimed |
| WO-2005073197-A1 | DERIVATIVES OF N-` (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | WO | claimed |
| EP-1720837-B1 | DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY | SANOFI AVENTIS (FR) | 2010-04-28 | — | — | EP | disclosed |
| US-7294645-B2 | Derivatives of N′-(1,5-diphenyl-1H-pyrazol-3-yl) sulfonamide with CB1 receptor affinity | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070021486-A1 | DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE WITH CB1 RECEPTOR AFFINITY | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1720837-A1 | DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY | Sanofi-Aventis (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005073197-A1 | DERIVATIVES OF N-` (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021486-A1 | DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE WITH CB1 RECEPTOR AFFINITY | CNR1, CNR2, NPSR1 | CNR1 1/4885CNR2 2/4885KCNH2 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.